Latest Trovagene Inc. Stories
Precision Cancer Monitoring technology offers advantages over tissue biopsy and demonstrates ability to monitor tumor dynamics in lung, pancreatic, and colon cancers SAN DIEGO, May
NEW YORK, May 11, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Moments ago, Analysts Review released
Company moves three EGFR mutation assays into its CLIA lab, expands clinical study programs in lung cancer, and prepares to deploy commercial strategy and sales team ahead of ASCO SAN DIEGO,
Analysis concludes that use of Trovagene's urinary liquid biopsy significantly reduces costs when compared to tissue biopsy SAN DIEGO, May 4, 2015 /PRNewswire/ -- Trovagene, Inc.,
SAN DIEGO, April 28, 2015 /PRNewswire/ -- Trovagene, Inc.
Company's liquid biopsy technology features single molecule sensitivity and the ability to obtain significantly more circulating tumor DNA (ctDNA) from urine samples vs.
Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging
Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging innovative applications of next-generation sequencing SAN
Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care SAN DIEGO, March 12, 2015 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- Trovagene, Inc.
- A woman chauffeur.
- A woman who operates an automobile.